Similarly, H19, MIR2052HG, TINCR, DCST1-AS1, NONHSAT101069, and CASC2 are involved in fulvestrant, aromatase inhibitors, trastuzumab, doxorubicin, epirubicin, and paclitaxel resistance, respectively, in BC patients by way of different mechanisms [79]. This evidence concerns the gene H19 and breast cancer.